Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib studyB Schultheis, G Folprecht, J Kuhlmann, et al.
ESMO Open|September 5, 2021
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX studyK Klinghammer, J Fayette, A Kawecki, et al.
The Pharmacogenomics Journal|June 6, 2012
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)P M Wilson, D Yang, M Azuma, et al.
ESMO Open|July 24, 2025
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multicentre, single-arm phase II study (ILOC)J Seligmann, T Koessler, M Mauer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2017
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3D P Modest, T Denecke, J Pratschke, et al.
British Journal of Cancer|December 11, 2008
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trialG Huebner, H Link, C H Kohne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)G Folprecht, T Gruenberger, W Bechstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM studyG Folprecht, C Pericay, M P Saunders, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'G Folprecht, M Morfouace, M Collienne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2014
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetH Blons, J F Emile, K Le Malicot, et al.
Pageof 4